AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.090

+0.0033.45%

Volume:543.20K

Turnover:49.06K

Market Cap:70.58M

PE:-5.11

High:0.093

Open:0.088

Low:0.087

Close:0.087

52wk High:0.150

52wk Low:0.053

Shares:784.22M

Float Shares:351.37M

Volume Ratio:1.09

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:5.55

PE(LYR):-5.11

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Neurizon Says US FDA Affirms Phase 2/3 ALS Drug Trial as Potentially Registrational; Shares Up 5%

MT Newswires Live

Australia's Neurizon Jumps on Potential for Neurodegenerative Drug Approval

Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed by FDA

Neurizon Therapeutics - FDA Type C Meeting Affirms Ongoing Healey ALS Platform Trial as Potentially Registrational

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/NUZ.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.09,"timestamp":1791436320000,"preClose":0.087,"halted":0,"volume":543197,"delay":0,"changeRate":0.03448275862068969,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"Closed","change":0.003,"latestTime":"10-08 16:12:00 AEDT","open":0.088,"high":0.093,"low":0.087,"amount":49058,"amplitude":0.068966,"askPrice":0.094,"askSize":200000,"bidPrice":0.09,"bidSize":35000,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.087,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.09284,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.087,"auctionPrice":0.087,"auctionVolume":38,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349799229}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":1.09284,"shares":784215600,"dividePrice":0,"high":0.093,"amplitude":0.068966,"preClose":0.087,"low":0.087,"week52Low":0.053,"pbRate":"5.55","psRate":"4.01","week52High":0.15,"institutionHeld":0,"latestPrice":0.09,"committee":-0.702128,"eps":-0.0176,"divideRate":0,"volume":543197,"delay":0,"ttmEps":-0.0176,"open":0.088,"prevYearClose":0.085,"prevWeekClose":0.08,"prevMonthClose":0.078,"prevQuarterClose":0.078,"fiveDayClose":0.075,"twentyDayClose":0.078,"sixtyDayClose":0.063,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673363520","title":"Neurizon Says US FDA Affirms Phase 2/3 ALS Drug Trial as Potentially Registrational; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673363520","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673363520?lang=en_us&edition=fundamental","pubTime":"2026-10-06 12:31","pubTimestamp":1791261074,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  received written responses from the US Food and Drug Administration  to its type C meeting request for NUZ-001, a treatment candidate for amyotrophic lateral sclerosis , affirming that positive results from its phase 2/3 trial may support a traditional approval pathway, according to a Tuesday Australian bourse filing.The US FDA agreed with the company's approach to measuring plasma neurofilament light chain, a marker of nerve damage, and outlined the types of evidence that would be needed for neurofilament light chain to support accelerated approval.The regulator noted that the trial may serve as the single registrational study for a new drug application, subject to meeting the requirement for substantial evidence of effectiveness, including supporting evidence alongside the study results.The clinical-stage biotech company's shares rose nearly 5% in recent trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","BK7096","BK4588","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673038336","title":"Australia's Neurizon Jumps on Potential for Neurodegenerative Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2673038336","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673038336?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:09","pubTimestamp":1791248996,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon jumps on potential for neurodegenerative drug approval** Shares of Neurizon TherapeuticsNUZ.AXrise as much as 14.3% to A$0.096, their highest level since March 13** Biotech c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087952","title":"Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087952?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:01","pubTimestamp":1791241288,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDAOct 6 (Reuters)-Neurizon Therapeutics LtdNUZ.AX:FDA TYPE C MEETING AFFIRMS ONGOING HEALEY ALS PLATFORM TRIAL AS POTENTIALLY REGISTRATIONALFurther company coverage:NUZ.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673876910","title":"Neurizon Therapeutics - FDA Type C Meeting Affirms Ongoing Healey ALS Platform Trial as Potentially Registrational","url":"https://stock-news.laohu8.com/highlight/detail?id=2673876910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673876910?lang=en_us&edition=fundamental","pubTime":"2026-10-06 06:58","pubTimestamp":1791241105,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NUZ.AU\",params:#limit:6,delay:true,,,undefined,":[]}}